Page last updated: 2024-11-12

ouabagenin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ouabagenin: inhibitor of ATPASE; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ouabagenin : A hexahydroxy steroidal lactone obtained by hydrolysis of ouabain. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID12313812
CHEMBL ID2068926
CHEBI ID71016
SCHEMBL ID643840
MeSH IDM0052815

Synonyms (25)

Synonym
4-18-00-03554 (beilstein handbook reference)
r2692w2t67 ,
unii-r2692w2t67
1-beta,3-beta,5,11-alpha,14,19-hexahydroxy-5-beta-card-20(22)-enolide
card-20(22)-enolide, 1,3,5,11,14,19-hexahydroxy-, (1-beta,3-beta,5-beta,11-alpha)-
5-beta-card-20(22)-enolide, 1-beta,3-beta,5,11-alpha,14,19-hexahydroxy-
brn 0060306
nsc 97088
5beta-card-20(22)-enolide, 1beta,3beta,5,11alpha,14,19-hexahydroxy-
g-strophanthidin
ouabain genin
ouabagenin
nsc-97088
508-52-1
ouabagenin, >=95%
CHEMBL2068926
1beta,3beta,5,11alpha,14,19-hexahydroxy-5beta-card-20(22)-enolide
CHEBI:71016 ,
SCHEMBL643840
1.beta.,3.beta.,5,11.alpha.,14,19-hexahydroxy-5.beta.-20(22)-cardenolide
ouabagenin [mi]
card-20(22)-enolide, 1,3,5,11,14,19-hexahydroxy-, (1.beta.,3.beta.,5.beta.,11.alpha.)-
Q1724241
3-[(1r,3s,5s,8r,9s,10r,11r,13r,14s,17r)-1,3,5,11,14-pentahydroxy-10-(hydroxymethyl)-13-methyl-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2h-furan-5-one
DTXSID901026559

Research Excerpts

Overview

Ouabagenin (OBG) is an aglycone of the cardiotonic steroid ouabain. Until now was considered a biologically inactive biosynthetic precursor.

ExcerptReferenceRelevance
"Ouabagenin (OBG) is an aglycone of the cardiotonic steroid ouabain and until now was considered a biologically inactive biosynthetic precursor. "( Ouabagenin is a naturally occurring LXR ligand without causing hepatic steatosis as a side effect.
Fukunaga, K; Kato, S; Okada, M; Shinoda, Y; Shioda, N; Tamura, S; Ueda, M; Ui-Tei, K, 2018
)
3.37

Toxicity

ExcerptReferenceRelevance
" In addition, OBG repressed the expression of epithelial sodium channel (ENaC), a LXR target gene, without causing hepatic steatosis, a typical side effect of conventional LXR ligands."( Ouabagenin is a naturally occurring LXR ligand without causing hepatic steatosis as a side effect.
Fukunaga, K; Kato, S; Okada, M; Shinoda, Y; Shioda, N; Tamura, S; Ueda, M; Ui-Tei, K, 2018
)
1.92
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitorAn EC 3.6.3.* (acid anhydride hydrolase catalysing transmembrane movement of substances) inhibitor that interferes with the action of Na(+)/K(+)-transporting ATPase (EC 3.6.3.9).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
3beta-hydroxy steroidA 3-hydroxy steroid in which the 3-hydroxy substituent is in the beta-position.
1-hydroxy steroidA hydroxy steroid having a hydroxy group located at position 1.
5beta-hydroxy steroid
11alpha-hydroxy steroid
14beta-hydroxy steroidA 14-hydroxy steroid in which the hydroxy group has a beta-configuration.
19-hydroxy steroid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID127351Binding affinity against human monoclonal antibody (mAb)-5C22002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
AID127350Binding affinity against human monoclonal antibody (mAb)-1B32002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
AID127479Binding affinity against murine monoclonal antibody (mAb)-40-502002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
AID127349Binding affinity against human monoclonal antibody (mAb)-11E62002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
AID127352Binding affinity against human monoclonal antibody (mAb)-7F22002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (37)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (24.32)18.7374
1990's8 (21.62)18.2507
2000's9 (24.32)29.6817
2010's9 (24.32)24.3611
2020's2 (5.41)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.18 (24.57)
Research Supply Index3.71 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (2.56%)5.53%
Reviews1 (2.56%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other37 (94.87%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]